This report was recently updated on November 15 2024 with the latest and most recent
market numbers
Global In-Vivo Gene Editing Market Size, Trends & Analysis - Forecasts to 2029 By Technology Type (CRISPR-Cas9, Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), and Other Gene Editing Technologies), By Application (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, and Other Therapeutic Areas), and By Region (North America, Asia Pacific, Central and South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global in-vivo gene editing market is projected to grow at a CAGR of 15.1% from 2024 to 2029.
Advances in gene editing technologies such as CRISPR-Cas9, TALENs, and ZFNs have significantly enhanced the precision and efficiency of in-vivo gene editing. These advancements have accelerated market expansion by providing more effective tools for targeted genetic manipulation. Enhanced precision reduces off-target effects, contributing to safety and efficacy in treating genetic disorders. Technological advancements attract research funding and investments, contributing to market growth.
Increased investment in R&D efforts, particularly those aimed at gene therapy and genetic illnesses, has created a growing demand for in-vivo gene editing technology. This increase in R&D funding indicates an increasing emphasis on treating common genetic diseases and developing novel therapeutic approaches. Such investments enable the discovery of new applications and the development of existing technologies, driving progress in the sector. As a result, the growing demand for in-vivo gene editing technologies is driven by the broadening breadth of research initiatives and the search for more effective genetic treatments.
The rising prevalence of genetic illnesses such as cancer, hemophilia, sickle cell disease, and muscular dystrophy has created a significant market need for in-vivo gene editing medicines designed to treat these conditions. This trend reflects an increasing realization of the need for effective treatments to address the genetic variables that contribute to these disorders. In-vivo gene editing provides a potential route for targeted therapies to fix genetic abnormalities and reduce the severity of certain illnesses. As a result, the increasing prevalence of genetic diseases contributes significantly to the growing market need for in-vivo gene editing therapies customized to these specific conditions.
Despite breakthroughs, gene editing techniques may still produce off-target effects, resulting in unintentional changes in the genome that could raise safety concerns and impede regulatory approval.
The CRISPR-cas9 segment is expected to hold the largest share in the market. The segment's growth is due to its variety, simplicity, and efficiency in targeting specific genes to modify. CRISPR-Cas9's widespread adoption in research and therapeutic applications, together with ongoing developments to improve its precision and efficacy, make it the top choice for in-vivo gene editing efforts.
The transcription activator-like effector nucleases (TALENs) segment is expected to be the fastest-growing segment in the market from 2024 to 2029. TALENs are highly specific and efficient in gene editing, equivalent to CRISPR-Cas9, with less off-target consequences. Furthermore, continuous research and development activities to optimize TALEN technology contribute to its expected growth of the market.
The cancer segment is anticipated to be the fastest-growing segment in the market from 2024 to 2029. The segment's growth is due to increased research on creating precision oncology medicines. In-vivo gene editing technologies provide intriguing techniques for boosting cancer therapy efficacy by targeting oncogenes, altering tumor suppressor genes, and strengthening immune responses to cancer cells.
The genetic disorders segment is expected to hold the largest share of the market. The growth of the segment is attributed to the critical need for effective treatments for inherited disorders such as cystic fibrosis, sickle cell disease, and muscular dystrophy. In-vivo gene editing provides prospective options for directly repairing disease-causing mutations within patients, thereby driving market growth.
North America is expected to be the largest region in the market. The primary reasons boosting the market growth in this region include significant investments in biotechnology R&D, a well-established healthcare infrastructure, and a favorable regulatory environment. Furthermore, major biotechnology and pharmaceutical businesses, academic institutions, and research institutes in North America contribute to the region's market dominance.
Asia Pacific is predicted to witness rapid growth during the forecast period. The regional market growth is attributed to the increasing investments in biotechnology and genetic research, the rising prevalence of genetic disorders, expanding healthcare infrastructure, and the growing use of breakthrough medical technologies. Furthermore, supportive government initiatives and collaborations with foreign research institutions promote the development and use of in-vivo gene editing technologies in the region.
Precision BioSciences, Inc., Homology Medicines, Inc., Ensomo, Applied StemCell, Sanofi, Intellia Therapeutics Inc., Editas Medicine, CRISPR Therapeutics, Sangamo Therapeutics, Beam Therapeutics, and Synthego Corporation, among others, are some of the key players operating in the global in-vivo gene editing market.
Please note: This is not an exhaustive list of companies profiled in the report.
In April 2024, Precision BioSciences recently announced the return of three of their older programs from Prevail Therapeutics, which is a subsidiary of Eli Lilly and Company. The collaboration between Precision BioSciences and Prevail Therapeutics was productive, advancing three programs towards clinical development and demonstrating proof of concept for ARCUS gene editing technology in gene excision and insertion.
In January 2024, Scribe Therapeutics and Sanofi expanded their collaboration to develop in vivo CRISPR-based therapeutics, with Sanofi exercising its option for a second target. This collaboration aims to leverage Scribe's CRISPR by Design approach, which optimizes CRISPR-based platforms and assets for the development of genetic medicines.
In October 2023, Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. announced an expanded research collaboration aimed at developing additional in vivo CRISPR-based gene editing therapies for neurological and muscular diseases. This collaboration builds upon the success of their existing partnership and combines the expertise of both companies in biology and technology.
In February 2024, CRISPR Therapeutics received conditional marketing authorization from the European Commission for CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy. This approval marks a significant milestone, making CASGEVY the first CRISPR/Cas9 therapy to be approved for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in the European Union (EU).
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
3 GLOBAL MARKET OUTLOOK
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL IN-VIVO GENE EDITING MARKET, BY TECHNOLOGY TYPE
4.1 Introduction
4.2 In-Vivo Gene Editing Market: Technology Type Scope Key Takeaways
4.3 Revenue Growth Analysis, 2023 & 2029
4.4 CRISPR-Cas9
4.4.1 CRISPR-Cas9 Market Estimates and Forecast, 2021-2029 (USD Million)
4.5 Zinc Finger Nucleases (ZFNs)
4.5.1 Zinc Finger Nucleases (ZFNs) Market Estimates and Forecast, 2021-2029 (USD Million)
4.6 Transcription Activator-Like Effector Nucleases (TALENs)
4.6.1 Transcription Activator-Like Effector Nucleases (TALENs) Market Estimates and Forecast, 2021-2029 (USD Million)
4.7 Other Gene Editing Technologies
4.7.1 Other Gene Editing Technologies Market Estimates and Forecast, 2021-2029 (USD Million)
5 GLOBAL IN-VIVO GENE EDITING MARKET, BY APPLICATION
5.1 Introduction
5.2 In-Vivo Gene Editing Market: Application Scope Key Takeaways
5.3 Revenue Growth Analysis, 2023 & 2029
5.4 Genetic Disorders
5.4.1 Genetic Disorders Market Estimates and Forecast, 2021-2029 (USD Million)
5.5 Cancer
5.5.1 Cancer Market Estimates and Forecast, 2021-2029 (USD Million)
5.6 Infectious Diseases
5.6.1 Infectious Diseases Market Estimates and Forecast, 2021-2029 (USD Million)
5.7 Neurological Disorders
5.7.1 Neurological Disorders Market Estimates and Forecast, 2021-2029 (USD Million)
5.8 Other Therapeutic Areas
5.8.1 Other Therapeutic Areas Market Estimates and Forecast, 2021-2029 (USD Million)
6 GLOBAL IN-VIVO GENE EDITING MARKET, BY REGION
6.1 Introduction
6.2 North America In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.1 By Technology Type
6.2.2 By Application
6.2.3 By Country
6.2.3.1 U.S. In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.1.1 By Technology Type
6.2.3.1.2 By Application
6.2.3.2 Canada In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.2.1 By Technology Type
6.2.3.2.2 By Application
6.2.3.3 Mexico In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.3.1 By Technology Type
6.2.3.3.2 By Application
6.3 Europe In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.1 By Technology Type
6.3.2 By Application
6.3.3 By Country
6.3.3.1 Germany In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.1.1 By Technology Type
6.3.3.1.2 By Application
6.3.3.2 U.K. In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.2.1 By Technology Type
6.3.3.2.2 By Application
6.3.3.3 France In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.3.1 By Technology Type
6.3.3.3.2 By Application
6.3.3.4 Italy In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.4.1 By Technology Type
6.3.3.4.2 By Application
6.3.3.5 Spain In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.5.1 By Technology Type
6.3.3.5.2 By Application
6.3.3.6 Netherlands In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.6.1 By Technology Type
6.3.3.6.2 By Application
6.3.3.7 Rest of Europe In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.6.1 By Technology Type
6.3.3.6.2 By Application
6.4 Asia Pacific In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.1 By Technology Type
6.4.2 By Application
6.4.3 By Country
6.4.3.1 China In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.1.1 By Technology Type
6.4.3.1.2 By Application
6.4.3.2 Japan In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.2.1 By Technology Type
6.4.3.2.2 By Application
6.4.3.3 India In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.3.1 By Technology Type
6.4.3.3.2 By Application
6.4.3.4 South Korea In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.4.1 By Technology Type
6.4.3.4.2 By Application
6.4.3.5 Singapore In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.5.1 By Technology Type
6.4.3.5.2 By Application
6.4.3.6 Malaysia In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.6.1 By Technology Type
6.4.3.6.2 By Application
6.4.3.7 Thailand In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.6.1 By Technology Type
6.4.3.6.2 By Application
6.4.3.8 Indonesia In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.7.1 By Technology Type
6.4.3.7.2 By Application
6.4.3.9 Vietnam In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.8.1 By Technology Type
6.4.3.8.2 By Application
6.4.3.10 Taiwan In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.10.1 By Technology Type
6.4.3.10.2 By Application
6.4.3.11 Rest of Asia Pacific In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.11.1 By Technology Type
6.4.3.11.2 By Application
6.5 Middle East and Africa In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.1 By Technology Type
6.5.2 By Application
6.5.3 By Country
6.5.3.1 Saudi Arabia In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.1.1 By Technology Type
6.5.3.1.2 By Application
6.5.3.2 U.A.E. In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.2.1 By Technology Type
6.5.3.2.2 By Application
6.5.3.3 Israel In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.3.1 By Technology Type
6.5.3.3.2 By Application
6.5.3.4 South Africa In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.4.1 By Technology Type
6.5.3.4.2 By Application
6.5.3.5 Rest of Middle East and Africa In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.5.1 By Technology Type
6.5.3.5.2 By Application
6.6 Central and South America In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.1 By Technology Type
6.6.2 By Application
6.6.3 By Country
6.6.3.1 Brazil In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.1.1 By Technology Type
6.6.3.1.2 By Application
6.6.3.2 Argentina In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.2.1 By Technology Type
6.6.3.2.2 By Application
6.6.3.3 Chile In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.3.1 By Technology Type
6.6.3.3.2 By Application
6.6.3.3 Rest of Central and South America In-Vivo Gene Editing Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.3.1 By Technology Type
6.6.3.3.2 By Application
7 COMPETITIVE LANDCAPE
7.1 Company Market Share Analysis
7.2 Four Quadrant Positioning Matrix
7.2.1 Market Leaders
7.2.2 Market Visionaries
7.2.3 Market Challengers
7.2.4 Niche Market Players
7.3 Vendor Landscape
7.3.1 North America
7.3.2 Europe
7.3.3 Asia Pacific
7.3.4 Rest of the World
7.4 Company Profiles
7.4.1 Precision BioSciences, Inc.
7.4.1.1 Business Description & Financial Analysis
7.4.1.2 SWOT Analysis
7.4.1.3 Products & Services Offered
7.4.1.4 Strategic Alliances between Business Partners
7.4.2 Homology Medicines, Inc.
7.4.2.1 Business Description & Financial Analysis
7.4.2.2 SWOT Analysis
7.4.2.3 Products & Services Offered
7.4.2.4 Strategic Alliances between Business Partners
7.4.3 Ensomo
7.4.3.1 Business Description & Financial Analysis
7.4.3.2 SWOT Analysis
7.4.3.3 Products & Services Offered
7.4.3.4 Strategic Alliances between Business Partners
7.4.4 Applied StemCell
7.4.4.1 Business Description & Financial Analysis
7.4.4.2 SWOT Analysis
7.4.4.3 Products & Services Offered
7.4.4.4 Strategic Alliances between Business Partners
7.4.5 Sanofi
7.4.5.1 Business Description & Financial Analysis
7.4.5.2 SWOT Analysis
7.4.5.3 Products & Services Offered
7.4.5.4 Strategic Alliances between Business Partners
7.4.6 Intellia Therapeutics Inc.
7.4.6.1 Business Description & Financial Analysis
7.4.6.2 SWOT Analysis
7.4.6.3 Products & Services Offered
7.4.6.4 Strategic Alliances between Business Partners
7.4.7 Editas Medicine
7.4.7.1 Business Description & Financial Analysis
7.4.7.2 SWOT Analysis
7.4.7.3 Products & Services Offered
7.4.7.4 Strategic Alliances between Business Partners
7.4.8 CRISPR Therapeutics
7.4.8.1 Business Description & Financial Analysis
7.4.8.2 SWOT Analysis
7.4.8.3 Products & Services Offered
7.4.8.4 Strategic Alliances between Business Partners
7.4.9 Sangamo Therapeutics
7.4.9.1 Business Description & Financial Analysis
7.4.9.2 SWOT Analysis
7.4.9.3 Products & Services Offered
7.4.9.4 Strategic Alliances between Business Partners
7.4.10 Beam Therapeutics
7.4.10.1 Business Description & Financial Analysis
7.4.10.2 SWOT Analysis
7.4.10.3 Products & Services Offered
7.4.10.4 Strategic Alliances between Business Partners
7.4.11 Synthego Corporation
7.4.11.1 Business Description & Financial Analysis
7.4.11.2 SWOT Analysis
7.4.11.3 Products & Services Offered
7.4.11.4 Strategic Alliances between Business Partners
7.4.12 Other Companies
7.4.12.1 Business Description & Financial Analysis
7.4.12.2 SWOT Analysis
7.4.12.3 Products & Services Offered
7.4.12.4 Strategic Alliances between Business Partners
8 RESEARCH METHODOLOGY
8.1 Market Introduction
8.1.1 Market Definition
8.1.2 Market Scope & Segmentation
8.2 Information Procurement
8.2.1 Secondary Research
8.2.1.1 Purchased Databases
8.2.1.2 GMEs Internal Data Repository
8.2.1.3 Secondary Resources & Third Party Perspectives
8.2.1.4 Company Information Sources
8.2.2 Primary Research
8.2.2.1 Various Types of Respondents for Primary Interviews
8.2.2.2 Number of Interviews Conducted throughout the Research Process
8.2.2.3 Primary Stakeholders
8.2.2.4 Discussion Guide for Primary Participants
8.2.3 Expert Panels
8.2.3.1 Expert Panels Across 30+ Industry
8.2.4 Paid Local Experts
8.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
8.3 Market Estimation
8.3.1 Top-Down Approach
8.3.1.1 Macro-Economic Indicators Considered
8.3.1.2 Micro-Economic Indicators Considered
8.3.2 Bottom Up Approach
8.3.2.1 Company Share Analysis Approach
8.3.2.2 Estimation of Potential Product Sales
8.4 Data Triangulation
8.4.1 Data Collection
8.4.2 Time Series, Cross Sectional & Panel Data Analysis
8.4.3 Cluster Analysis
8.5 Analysis and Output
8.5.1 Inhouse AI Based Real Time Analytics Tool
8.5.2 Output From Desk & Primary Research
8.6 Research Assumptions & Limitations
8.6.1 Research Assumptions
8.6.2 Research Limitations
LIST OF TABLES
1 Global In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
2 CRISPR-Cas9 Market, By Region, 2021-2029 (USD Mllion)
3 Zinc Finger Nucleases (ZFNs) Market, By Region, 2021-2029 (USD Mllion)
4 Transcription Activator-Like Effector Nucleases (TALENs) Market, By Region, 2021-2029 (USD Mllion)
5 Other Gene Editing Technologies Market, By Region, 2021-2029 (USD Mllion)
6 Global In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
7 Genetic Disorders Market, By Region, 2021-2029 (USD Mllion)
8 Cancer Market, By Region, 2021-2029 (USD Mllion)
9 Infectious Diseases Market, By Region, 2021-2029 (USD Mllion)
10 Neurological Disorders Market, By Region, 2021-2029 (USD Mllion)
11 Other Therapeutic Areas Market, By Region, 2021-2029 (USD Mllion)
12 Regional Analysis, 2021-2029 (USD Mllion)
13 North America In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
14 North America In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
15 North America In-Vivo Gene Editing Market, By COUNTRY, 2021-2029 (USD Mllion)
16 U.S. In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
17 U.S. In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
18 Canada In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
19 Canada In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
20 Mexico In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
21 Mexico In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
22 Europe In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
23 Europe In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
24 Europe In-Vivo Gene Editing Market, By Country, 2021-2029 (USD Mllion)
25 Germany In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
26 Germany In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
27 U.K. In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
28 U.K. In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
29 France In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
30 France In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
31 Italy In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
32 Italy In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
33 Spain In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
34 Spain In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
35 Netherlands In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
36 Netherlands In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
37 Rest Of Europe In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
38 Rest Of Europe In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
39 Asia Pacific In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
40 Asia Pacific In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
41 Asia Pacific In-Vivo Gene Editing Market, By Country, 2021-2029 (USD Mllion)
42 China In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
43 China In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
44 Japan In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
45 Japan In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
46 India In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
47 India In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
48 South Korea In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
49 South Korea In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
50 Singapore In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
51 Singapore In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
52 Thailand In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
53 Thailand In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
54 Malaysia In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
55 Malaysia In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
56 Indonesia In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
57 Indonesia In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
58 Vietnam In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
59 Vietnam In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
60 Taiwan In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
61 Taiwan In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
62 Rest of APAC In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
63 Rest of APAC In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
64 Middle East and Africa In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
65 Middle East and Africa In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
66 Middle East and Africa In-Vivo Gene Editing Market, By Country, 2021-2029 (USD Mllion)
67 Saudi Arabia In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
68 Saudi Arabia In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
69 UAE In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
70 UAE In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
71 Israel In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
72 Israel In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
73 South Africa In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
74 South Africa In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
75 Rest Of Middle East and Africa In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
76 Rest Of Middle East and Africa In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
77 Central and South America In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
78 Central and South America In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
79 Central and South America In-Vivo Gene Editing Market, By Country, 2021-2029 (USD Mllion)
80 Brazil In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
81 Brazil In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
82 Chile In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
83 Chile In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
84 Argentina In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
85 Argentina In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
86 Rest Of Central and South America In-Vivo Gene Editing Market, By Technology Type, 2021-2029 (USD Mllion)
87 Rest Of Central and South America In-Vivo Gene Editing Market, By Application, 2021-2029 (USD Mllion)
88 Precision BioSciences, Inc.: Products & Services Offering
89 Homology Medicines, Inc.: Products & Services Offering
90 Ensomo: Products & Services Offering
91 Applied StemCell: Products & Services Offering
92 Sanofi: Products & Services Offering
93 INTELLIA THERAPEUTICS INC.: Products & Services Offering
94 Editas Medicine : Products & Services Offering
95 CRISPR Therapeutics: Products & Services Offering
96 Sangamo Therapeutics, Inc: Products & Services Offering
97 Beam Therapeutics: Products & Services Offering
98 Synthego Corporation Companies: Products & Services Offering
99 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global In-Vivo Gene Editing Market Overview
2 Global In-Vivo Gene Editing Market Value From 2021-2029 (USD Mllion)
3 Global In-Vivo Gene Editing Market Share, By Technology Type (2023)
4 Global In-Vivo Gene Editing Market Share, By Application (2023)
5 Global In-Vivo Gene Editing Market, By Region (Asia Pacific Market)
6 Technological Trends In Global In-Vivo Gene Editing Market
7 Four Quadrant Competitor Positioning Matrix
8 Impact Of Macro & Micro Indicators On The Market
9 Impact Of Key Drivers On The Global In-Vivo Gene Editing Market
10 Impact Of Challenges On The Global In-Vivo Gene Editing Market
11 Porter’s Five Forces Analysis
12 Global In-Vivo Gene Editing Market: By Technology Type Scope Key Takeaways
13 Global In-Vivo Gene Editing Market, By Technology Type Segment: Revenue Growth Analysis
14 CRISPR-Cas9 Market, By Region, 2021-2029 (USD Mllion)
15 Zinc Finger Nucleases (ZFNs) Market, By Region, 2021-2029 (USD Mllion)
16 Other Gene Editing TechnologiesMarket, By Region, 2021-2029 (USD Mllion)
17 Transcription Activator-Like Effector Nucleases (TALENs) Market, By Region, 2021-2029 (USD Mllion)
18 Global In-Vivo Gene Editing Market: By Application Scope Key Takeaways
19 Global In-Vivo Gene Editing Market, By Application Segment: Revenue Growth Analysis
20 Genetic Disorders Market, By Region, 2021-2029 (USD Mllion)
21 Cancer Market, By Region, 2021-2029 (USD Mllion)
22 Infectious Diseases Market, By Region, 2021-2029 (USD Mllion)
23 Neurological Disorders Market, By Region, 2021-2029 (USD Mllion)
24 Other Therapeutic Areas Market, By Region, 2021-2029 (USD Mllion)
25 Regional Segment: Revenue Growth Analysis
26 Global In-Vivo Gene Editing Market: Regional Analysis
27 North America In-Vivo Gene Editing Market Overview
28 North America In-Vivo Gene Editing Market, By Technology Type
29 North America In-Vivo Gene Editing Market, By Application
30 North America In-Vivo Gene Editing Market, By Country
31 U.S. In-Vivo Gene Editing Market, By Technology Type
32 U.S. In-Vivo Gene Editing Market, By Application
33 Canada In-Vivo Gene Editing Market, By Technology Type
34 Canada In-Vivo Gene Editing Market, By Application
35 Mexico In-Vivo Gene Editing Market, By Technology Type
36 Mexico In-Vivo Gene Editing Market, By Application
37 Four Quadrant Positioning Matrix
38 Company Market Share Analysis
39 Precision BioSciences, Inc.: Company Snapshot
40 Precision BioSciences, Inc.: SWOT Analysis
41 Precision BioSciences, Inc.: Geographic Presence
42 Homology Medicines, Inc.: Company Snapshot
43 Homology Medicines, Inc.: SWOT Analysis
44 Homology Medicines, Inc.: Geographic Presence
45 Ensomo: Company Snapshot
46 Ensomo: SWOT Analysis
47 Ensomo: Geographic Presence
48 Applied StemCell: Company Snapshot
49 Applied StemCell: Swot Analysis
50 Applied StemCell: Geographic Presence
51 Sanofi: Company Snapshot
52 Sanofi: SWOT Analysis
53 Sanofi: Geographic Presence
54 Intellia Therapeutics Inc.: Company Snapshot
55 Intellia Therapeutics Inc.: SWOT Analysis
56 Intellia Therapeutics Inc.: Geographic Presence
57 Editas Medicine : Company Snapshot
58 Editas Medicine : SWOT Analysis
59 Editas Medicine : Geographic Presence
60 CRISPR Therapeutics: Company Snapshot
61 CRISPR Therapeutics: SWOT Analysis
62 CRISPR Therapeutics: Geographic Presence
63 Sangamo Therapeutics, Inc.: Company Snapshot
64 Sangamo Therapeutics, Inc.: SWOT Analysis
65 Sangamo Therapeutics, Inc.: Geographic Presence
66 Beam Therapeutics: Company Snapshot
67 Beam Therapeutics: SWOT Analysis
68 Beam Therapeutics: Geographic Presence
69 Synthego Corporation: Company Snapshot
70 Synthego Corporation: SWOT Analysis
71 Synthego Corporation: Geographic Presence
72 Other Companies: Company Snapshot
73 Other Companies: SWOT Analysis
74 Other Companies: Geographic Presence
The Global In-Vivo Gene Editing Market has been studied from the year 2019 till 2029. However, the CAGR provided in the report is from the year 2024 to 2029. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the In-Vivo Gene Editing Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
